查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1844118

T細胞療法市場按最終用戶、細胞來源、適應症、療法類型和生產模式分類—2025-2032年全球預測

T-Cell Therapy Market by End User, Cell Source, Indication, Therapy Type, Manufacturing Model - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，T 細胞療法市場規模將達到 478.2 億美元，複合年成長率為 21.83%。

主要市場統計數據
基準年 2024 98.5億美元
預計年份：2025年 120.3億美元
預測年份：2032年 478.2億美元
複合年成長率 (%) 21.83%

臨床檢驗、生產製造成熟和醫療保健系統採納如何影響現代 T 細胞療法？

T細胞療法已從實驗科學發展成為先進免疫療法的關鍵支柱，徹底改變了臨床醫生和研發人員治療癌症、感染疾病和自體免疫疾病的方式。過去十年間，細胞工程、載體設計和生產流程的進步，以及反覆的臨床驗證，使得細胞產品從小眾臨床實驗藥物轉變為具有明確監管管道和商業化策略的成熟療法。

關鍵挑戰在於如何在保持科學研究動能的同時，克服與可擴展性、成本控制和全球供應鏈韌性相關的實際限制。隨著研發人員不斷改進抗原靶向性和持久性特徵，醫療系統和支付方必須改善其臨床價值和長期安全性的評估框架。同時，在決定一種療法的商業性命運方面，生產創新和策略夥伴關係與臨床差異化同樣至關重要。

因此，相關人員必須權衡近期業務決策與對平台技術、人才隊伍和監管參與的長期投資。本執行摘要的其餘部分概述了變革性轉變、細分資訊、區域動態以及領導者可用於加速臨床應用和永續商業化的實用建議。

基因工程、自動化製造和適應性監管的融合正在加速向平台主導T細胞療法生態系統的轉型。

在科學突破和營運規模化共同推動下，T細胞療法領域正經歷變革性的轉變。基因編輯工具和新一代受體工程技術拓展了可安全靶向的抗原類型，使得針對以往難以治療的適應症的個人化治療成為可能。同時，同種異體療法和現成T細胞製劑的成熟正在改變人們對治療時間和庫存管理的預期，進而影響研發者、製造外包和臨床試驗中心之間的關係。

製造業正從手工操作、以患者為中心的生產流程轉變為融合自動化、封閉式系統和模組化生產線的混合模式。這種運作模式的演變減少了人為因素的影響，縮短了批次週轉時間，並能夠支援更廣泛的臨床計畫。此外，生產數據和品質系統的數位化提高了可追溯性和合規性，同時也為應用預測分析最佳化產量比率創造了機會。

監管機構的參與和支付方的互動是另一個變革的驅動力。監管機構越來越接受適應性試驗設計和真實世界證據作為安全性和有效性數據的補充來源。同時，支付方要求提供能夠將臨床效用與持久療效和經濟價值結合的證據。這些壓力促使研發人員設計證據產生策略，將隨機數據與註冊研究和衛生經濟學模型結合。這些科學、管理和商業性的轉變正在加速從單一產品創新向平台主導的永續治療生態系統的轉變。

2025年貿易政策的累積影響加劇了供應鏈的敏感性，並促使製造模式和臨床實驗供應計畫發生策略性轉變。

美國2025年實施的關稅和貿易政策調整產生了累積影響，波及整個T細胞療法價值鏈，影響到原料投入、生產決策和國際合作。病毒載體、一次性耗材和專用試劑等關鍵原料的採購通常涉及跨境供應商。關稅增加了到岸成本，迫使企業重新評估供應商選擇、庫存策略和近期資本配置。

為此，許多開發商和受託製造製造商重新評估了其生產模式，權衡受託製造夥伴關係的優勢與自主生產的戰略控制權。經營全球供應鏈網路的公司增加了緩衝庫存，並實現了供應商多元化，以緩解關稅造成的價格波動。同時，一些公司加快了關鍵生產流程的在地化進程，將生產環節轉移到貿易協定更穩定的國家和地區，雖然這帶來了物流和監管方面的複雜性，但也減輕了進口關稅的影響。

在臨床方面，關稅帶來的成本壓力影響了檢測供應計劃和進度，尤其是依賴集中生產的多區域檢測。申辦方調整了受試者招募速度或採取了分散式生產策略，以維持檢測的連續性。商業性，不斷上漲的投入成本促使申辦方與支付方就創新合約和風險分擔機制展開更深入的討論，以因應不斷上漲的製造成本。總體而言，2025年關稅的累積影響凸顯了供應鏈對沖、靈活的生產佈局以及積極的相關人員合作對於維持臨床進展和商業性可行性的重要性。

跨臨床環境、細胞來源、適應症、治療方式和生產方案的深度細分智慧，能夠實現差異化的開發和商業策略。

細分市場分析揭示了不同臨床環境、生技藥品來源、治療重點、治療方式和交付模式的差異化策略需求。從終端使用者環境的角度來看，醫院仍然是提供複雜自體培養通訊協定的核心，這些方案需要受控的住院環境和多學科支援；研究機構繼續推動早期創新和轉化科學；隨著手術和支持性護理的日益標準化，專科診所也擴大採用門診通訊協定。

考慮細胞來源細分凸顯了同種異體和自體療法之間的根本權衡。自體構建體在監管方面有著悠久的歷史先例，並能提供個人化的抗原識別，但需要針對特定患者的生產物流。相反，同種異體構建體具有擴大治療規模和縮短療程的潛力，但需要考慮免疫抗原性和移植情況，因此需要個別化的臨床策略和生產控制。

適應症細分突顯了不同疾病領域治療重點和證據要求的差異。腫瘤治療需要持久緩解和對急性毒性的謹慎管理，而感染疾病和自體免疫疾病則需要不同的療效終點和安全性接受度。在自體免疫疾病中，多發性硬化症、乾癬和類風濕性關節炎等疾病具有獨特的病理生理標靶和患者群體，這些都會影響臨床試驗的設計。在感染疾病中，B型肝炎、C型肝炎和愛滋病需要客製化的病理學和免疫學終點。在腫瘤學領域，從白血病、淋巴瘤和多發性骨髓瘤等骨髓惡性腫瘤到乳癌、肺癌和黑色素瘤等固體癌，獨特的腫瘤微環境限制都會影響細胞遷移和持久性。

依治療方法類型細分，突顯了CAR-T細胞療法、TCR-T細胞療法和TIL療法在抗原辨識、生產複雜性和臨床應用方面的差異。 CAR-T細胞療法在血液系統骨髓惡性腫瘤中展現出強大的療效，並依賴人工構建的受體；TCR療法擴展了其抗原庫，使其包含細胞內靶點；而TIL療法則利用腫瘤駐留淋巴細胞來增強固態腫瘤的免疫抗原性。最後，按生產模式（將企業定位在契約製造和內部生產之間）進行細分，為企業在資本投資、品質體繫管理以及快速擴大生產規模以應對臨床或商業性需求方面提供了策略選擇框架。因此，每個細分維度都有助於確定研發投資、營運設計和打入市場策略的優先順序。

全球各地不同的法規環境、支付方特徵和生產能力將如何推動差異化的打入市場策略和供應鏈策略？

區域動態影響從臨床開發到商業化和供應鏈組織的策略重點。在美洲，強大的臨床試驗基礎設施、重點突出的醫保報銷談判以及雄厚的生產能力有利於加速臨床應用和早期商業化，但成本壓力和區域醫保報銷差異要求企業提出清晰的價值主張和創新的定價策略。

歐洲、中東和非洲監管體系的多樣性以及不同的衛生技術評估框架，使得針對特定區域的證據整合和支付方參與計畫成為必要。該地區是合作研究的中心，擁有越來越多的細胞療法製造地，為跨境臨床試驗網路和聯合生產聯盟提供了機遇，但報銷時間表往往會影響產品上市順序和市場准入管道。

亞太地區的特點是製造業產能投資快速成長、臨床試驗活動活性化，以及監管方式的多樣性，部分地區實施快速核准通道，而其他地區則尚處於起步階段。在地化生產和監管協調能夠創造競爭優勢，尤其對於那些尋求緩解貿易相關成本壓力並加快患者用藥速度的公司而言更是如此。因此，每個地區都需要製定量身定做的產業計畫，將監管預期、支付方環境、臨床能力和供應鏈因素相結合，以支持業務的永續擴張。

企業層面的競爭優勢日益來自平台科學、可擴展製造以及積極主動地與支付方和監管機構互動等綜合能力。

公司層級的關鍵競爭考察圍繞著能力整合、夥伴關係策略和垂直整合決策展開，這些因素將決定其競爭定位。領先的臨床階段公司正透過將受體工程專業知識與其轉化產品線相結合來拓展其適應症範圍，而其他公司則專注於提升其平台的穩健性，以支援多個候選產品。受託製造公司正在超越純粹的生產角色，轉型為提供製程開發、分析服務和品質源於設計能力的策略夥伴，從而幫助申辦方縮短臨床試驗時間。

研發公司、學術中心和生產供應商之間的策略夥伴關係日益普遍，從而能夠共用載體最佳化、效力檢測、冷凍保存技術等方面的專業知識。投資於模組化、自動化生產設備和數據整合品質系統的公司能夠靈活地管理不同類型的治療藥物，並擴大自體和異體藥物的生產規模。此外，積極與監管機構和支付方溝通並制定循證路徑的公司，將在市場准入談判中佔據優勢。

企業如何透過流程改善、供應鏈多元化和創新商業協議來應對服務成本挑戰，也是實現差異化競爭的關鍵。那些能夠平衡臨床差異化和卓越營運的企業，更有能力從小批量臨床供應過渡到可靠的商業分銷，同時滿足不斷變化的監管要求。

一份實用的領導力指南，旨在協調製造自動化、供應鏈多元化、證據產生和相關人員參與，以加速轉換和應用。

產業領導者應採取多管齊下的方法，將科學目標與實際操作結合。首先，應優先投資於製造自動化和封閉式系統製程開發，以降低變異性、減少對勞動力的依賴並加快交付速度。這項營運基礎能夠確保產品品質更加穩定，並支援對需求波動做出靈活響應。

第二，我們將實現關鍵投入品供應商網路的多元化，並實施策略性庫存措施，以降低因貿易波動和關稅造成的成本轉移風險。同時，我們將評估關鍵製造流程的近岸外包和本地化，以降低物流複雜性，並提高對本地市場的應對力。第三，我們將推行實證醫學策略，將隨機數據與真實世界結果以及註冊登記主導的縱向追蹤研究相結合，以滿足監管機構和支付方對持續效益的要求。

第四，在學術界、臨床和生產製造生態系統中建立夥伴關係，以利用外部資源，同時維持對核心平台技術的策略控制。第五，儘早與監管機構和支付方進行迭代式溝通，以確定測試終點、衛生經濟學模型和報銷機制，使臨床價值與永續定價一致。最後，透過制定基本契約框架和建立臨床支援計劃來加強商業性能力，從而促進在各種醫療環境中的應用。這些建議為應對複雜性、加速患者取得治療方案和提高商業性可行性提供了藍圖。

一項透明的三管齊下的調查方法結合了專家訪談、臨床和監管文件以及生產流程分析，從而提供可靠且可操作的見解。

本執行摘要的研究採用三角分析法，整合了第一手和第二手資料，以確保分析的嚴謹性和有效性。第一手資料包括對臨床實驗研究員、製造企業高管和監管顧問的結構化訪談，並輔以與支付方和醫院管理人員的諮詢會議，以了解營運和報銷方面的觀點。這些定性資訊與公開的監管文件、同行評審文獻和行業披露資訊進行系統比對，以檢驗趨勢並識別宣稱的能力與實際營運績效之間的差異。

數據分析整合了來自製造研討會的流程層面洞察，以及來自臨床註冊研究和已發表研究的測試設計和終點評估。在條件允許的情況下，我們採用調查方法三角驗證法，將訪談結果與文獻證據和專家小組的回饋進行交叉比對。品管程序包括對主題性觀察進行獨立審查、專家檢驗技術論斷，以及根據相關人員的回饋進行迭代改進。這種多層次的方法確保了結論既反映了當前技術水平，也反映了實際部署中遇到的運行限制。

將科學前景與營運需求結合，證明T細胞療法的永續商業化需要技術、監管和商業執行的整合。

T細胞療法在現代醫學中佔據著變革性的地位，有望為腫瘤、感染疾病和自體免疫疾病等多種適應症提供持久的解決方案。儘管該領域能夠帶來臨床突破，但也面臨供應鏈、生產和醫保報銷等方面的現實挑戰，這些挑戰決定著患者獲得治療的速度。對於那些致力於將科學前景轉化為持續的臨床和商業性影響的機構而言，在細胞來源、治療方法、生產模式和地理擴張等方面做出策略決策至關重要。

那些相關人員，很可能獲得競爭優勢。相反，那些低估臨床、生產和商業領域整合挑戰的利益相關者，則可能面臨延遲市場上市和限制應用的風險。總之，T細胞療法的持續成長需要持續的科學創新和價值鏈上嚴謹的執行。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 雙靶向CAR-T細胞療法的進展可提高腫瘤特異性和安全性
  • 整合 CRISPR 等基因編輯技術以增強 T 細胞的持久性和療效
  • 新興企業與製藥巨頭建立策略夥伴關係，加速T細胞療法的商業化進程
  • 照護現場製造平台的出現將縮短CAR-T細胞的生產時間和降低成本。
  • 將T細胞療法的應用範圍從腫瘤治療領域擴展到自體免疫感染疾病領域
  • 開發下一代可切換CAR-T細胞，實現可控活化以減輕細胞激素釋放症候群
  • 人工智慧和機器學習在最佳化T細胞生產和患者選擇方面的應用日益廣泛。
  • 不斷變化的監管環境為具有真實世界證據的T細胞療法提供了快速核准通道。
  • 利用基因組編輯技術建構通用供體T細胞平台，以預防移植物抗宿主疾病風險。

第6章美國關稅的累積影響，2025年

第7章 人工智慧的累積影響，2025年

第8章：按最終用戶分類的T細胞療法市場

  • 醫院
  • 研究所
  • 專科診所

第9章 T細胞療法市場：依細胞來源分類

  • 同種異體
  • 自體移植

第10章 依適應症分類的T細胞療法市場

  • 自體免疫疾病
    • 多發性硬化症
    • 銀屑病
    • 類風濕性關節炎
  • 感染疾病
    • B型肝炎
    • C型肝炎
    • HIV
  • 腫瘤學
    • 白血病
    • 淋巴瘤
    • 多發性骨髓瘤
    • 固態腫瘤
      • 乳癌
      • 肺癌
      • 黑色素瘤

第11章 T細胞療法市場按療法類型分類

  • CAR-T細胞療法
  • TCR T細胞療法
  • TIL治療

第12章：依生產模式分類的T細胞療法市場

  • 契約製造
  • 內部生產

第13章：按地區分類的T細胞療法市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 T細胞療法市集（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國T細胞療法市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Novartis AG
    • Kite Pharma, Inc.
    • Bristol-Myers Squibb Company
    • Janssen BIoTech, Inc.
    • Gilead Sciences, Inc.
Product Code: MRR-A26E0E5744D4

The T-Cell Therapy Market is projected to grow by USD 47.82 billion at a CAGR of 21.83% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 9.85 billion
Estimated Year [2025] USD 12.03 billion
Forecast Year [2032] USD 47.82 billion
CAGR (%) 21.83%

How clinical validation, manufacturing maturation, and health system adoption are collectively shaping the modern T-cell therapy landscape for near-term strategic planning

T-cell therapies have moved from experimental science to a critical pillar of advanced immunotherapy, reshaping how clinicians and developers approach treatment of oncology, infectious, and autoimmune conditions. Over the past decade, iterative clinical proof points combined with advances in cell engineering, vector design, and manufacturing processes have transitioned cellular products from niche investigational agents to therapies with defined regulatory pathways and commercialization strategies.

The industry now confronts a dual imperative: to sustain scientific momentum while solving practical constraints associated with scalability, cost management, and global supply chain resiliency. As developers refine antigen targeting and persistence profiles, healthcare systems and payers must evolve assessment frameworks for clinical value and long-term safety. Meanwhile, manufacturing innovations and strategic partnerships are becoming as decisive as clinical differentiation in determining a therapy's commercial fate.

Consequently, stakeholders must balance near-term operational decisions with longer-term investments in platform technologies, workforce capabilities, and regulatory engagement. The remainder of this executive summary synthesizes the transformative shifts, segmentation intelligence, regional dynamics, and pragmatic recommendations that leaders can leverage to accelerate clinical translation and sustainable commercialization.

Convergence of gene engineering, automated manufacturing, and adaptive regulatory engagement is accelerating the transition to platform-driven T-cell therapy ecosystems

The T-cell therapy landscape is undergoing transformative shifts driven by convergence of scientific breakthroughs and operational scaling. Gene editing tools and next-generation receptor engineering have expanded the kinds of antigens that can be safely targeted, enabling tailored approaches for previously intractable indications. Concurrently, the maturation of allogeneic strategies and off-the-shelf constructs is changing expectations around time-to-treatment and inventory management, which in turn alters the relationships between developers, contract manufacturers, and clinical sites.

Manufacturing has evolved from artisanal, patient-specific workflows to hybridized models that incorporate automation, closed systems, and modular production lines. This operational evolution reduces manual variability, compresses batch turnaround times, and enables capacity to support broader clinical programs. Furthermore, digitalization of production data and quality systems has improved traceability and regulatory readiness, while also creating opportunities to apply predictive analytics for yield optimization.

Regulatory engagement and payer interactions represent another axis of change. Authorities are increasingly receptive to adaptive trial designs and real-world evidence as complementary sources of safety and effectiveness data. At the same time, payers demand evidence that aligns clinical benefit with durable outcomes and economic value. These pressures are prompting developers to design evidence-generation strategies that blend randomized data with registries and health-economic modeling. In combination, these scientific, operational, and commercial shifts are accelerating a transition from single-product innovation to platform-driven, sustainable therapeutic ecosystems.

Cumulative trade policy effects in 2025 amplified supply chain sensitivities and prompted strategic shifts in manufacturing models and trial supply planning

The introduction of tariffs and trade policy adjustments in the United States during 2025 created a cumulative set of impacts that ripple through the T-cell therapy value chain, affecting inputs, manufacturing decisions, and international collaborations. Sourcing of critical raw materials such as viral vectors, single-use consumables, and specialized reagents often involves cross-border suppliers; tariffs increase landed costs and force organizations to reassess supplier selection, inventory strategies, and near-term capital allocation.

In response, many developers and contract manufacturers reevaluated their manufacturing models, weighing the benefits of contract manufacturing partnerships against the strategic control afforded by in-house production. Organizations operating global supply networks increased buffer inventories and diversified supplier bases to mitigate tariff-driven price volatility. At the same time, some companies accelerated localization of key production steps to jurisdictions with more stable trade arrangements, which created logistical and regulatory complexities but reduced exposure to import duties.

Clinically, tariff-driven cost pressures affected trial supply planning and timelines, particularly for multi-regional studies reliant on centralized manufacturing. Sponsors adjusted enrollment pacing or adopted decentralized manufacturing strategies to preserve trial continuity. Commercially, higher input costs intensified discussions with payers around innovative contracting and risk-sharing mechanisms that account for manufacturing cost inflation. Overall, the cumulative impact of tariffs in 2025 emphasized the need for supply chain hedging, flexible manufacturing footprints, and proactive stakeholder alignment to preserve both clinical momentum and commercial viability.

Deep segmentation intelligence across clinical settings, cell origins, indications, modalities, and manufacturing choices that informs differentiated development and commercial strategies

Segmentation analysis reveals differentiated strategic imperatives across clinical settings, biologic sourcing, therapeutic focus, modality, and operational delivery models. When viewing the market through the lens of end-user environments, hospitals remain central for delivering complex autologous protocols that require controlled inpatient settings and multidisciplinary support, whereas research institutes continue to drive early-phase innovation and translational science, and specialty clinics increasingly host outpatient-capable protocols as procedures and supportive care become more standardized.

Examining cell source segmentation underscores fundamental trade-offs between allogeneic and autologous approaches. Autologous constructs historically offered personalized antigen recognition with established regulatory precedents but required patient-specific manufacturing logistics. Conversely, allogeneic constructs promise scale and reduced time-to-treatment but introduce immunogenicity and engraftment considerations that necessitate distinct clinical strategies and manufacturing controls.

Indication segmentation highlights how therapeutic priorities and evidence requirements vary by disease area. Oncology programs demand durable remissions and careful management of acute toxicities, while infectious disease and autoimmune indications require different efficacy endpoints and safety tolerances. Within autoimmune diseases, conditions such as multiple sclerosis, psoriasis, and rheumatoid arthritis present distinct pathophysiologic targets and patient populations that influence trial design. For infectious diseases, hepatitis B, hepatitis C, and HIV each require tailored virologic and immunologic endpoints. Oncology indications span hematologic malignancies like leukemia, lymphoma, and multiple myeloma to solid tumors, where breast cancer, lung cancer, and melanoma each impose unique tumor microenvironmental constraints that affect cell trafficking and persistence.

Therapy type segmentation elucidates differences among CAR T cell therapy, TCR T cell therapy, and TIL therapy in terms of antigen recognition, manufacturing complexity, and clinical deployment. CAR T modalities offer robust responses in hematologic malignancies and rely on engineered receptor constructs, whereas TCR therapies expand the antigen repertoire including intracellular targets, and TIL therapies leverage tumor-resident lymphocytes for solid tumor immunogenicity. Finally, manufacturing model segmentation-positioning organizations between contract manufacturing and in-house production-frames strategic choices about capital investment, control over quality systems, and the ability to scale rapidly in response to clinical or commercial demand. Each segmentation axis therefore informs prioritization of R&D investments, operational design, and market engagement strategies.

How distinct regulatory environments, payer landscapes, and manufacturing capacities across global regions drive differentiated go-to-market and supply chain strategies

Regional dynamics shape strategic priorities from clinical development through commercialization and supply chain orchestration. In the Americas, robust clinical trial infrastructure, concentrated reimbursement dialogues, and substantial manufacturing capacity favor accelerated clinical translation and early commercial launches, but cost-containment pressures and regional reimbursement variability require clear value articulation and innovative pricing strategies.

In Europe, Middle East & Africa, regulatory heterogeneity and varying health technology assessment frameworks necessitate region-specific evidence packages and payer engagement plans. The region's collaborative academic hubs and growing cell therapy manufacturing footprint provide opportunities for cross-border trial networks and shared manufacturing consortia, while reimbursement timelines often influence launch sequencing and market access pathways.

The Asia-Pacific region is characterized by rapid investment in manufacturing capacity, increasing clinical trial activity, and diverse regulatory approaches that range from expedited pathways in some jurisdictions to nascent frameworks in others. Localized production and regulatory alignment efforts can create competitive advantages, particularly for companies seeking to mitigate trade-related cost pressures and accelerate patient access. Each region thus demands tailored operational plans that reconcile regulatory expectations, payer environments, clinical capabilities, and supply chain considerations to support sustainable expansion.

Company-level competitive advantage increasingly derives from integrated capabilities spanning platform science, scalable manufacturing, and proactive payer and regulatory engagement

Key company-level insights center on capability convergence, partnership strategies, and vertical integration decisions that determine competitive positioning. Leading clinical-stage organizations are combining receptor engineering expertise with translational pipelines to broaden indication coverage, while others focus on platform robustness to support multiple product candidates. Contract development and manufacturing organizations are evolving beyond pure production roles into strategic partners offering process development, analytical services, and quality-by-design capabilities that reduce time-to-clinic for sponsors.

Strategic partnerships between developers, academic centers, and manufacturing providers are increasingly common, enabling sharing of specialized knowledge such as vector optimization, potency assays, and cryopreservation techniques. Companies that invest in modular, automated manufacturing assets and data-integrated quality systems have greater flexibility to manage different therapy types and scale production across autologous and allogeneic formats. Additionally, those that proactively engage with regulators and payers to define evidence-generation pathways gain advantage in market access negotiations.

Competitive differentiation also emerges from how companies address cost-to-serve challenges through process intensification, supply chain diversification, and innovative commercial contracting. Organizations that balance clinical differentiation with operational excellence are better positioned to transition from small-batch clinical supply to reliable commercial distribution while maintaining compliance with evolving regulatory expectations.

A pragmatic playbook for leadership to align manufacturing automation, supply chain diversification, evidence generation, and stakeholder engagement to accelerate translation and adoption

Industry leaders should adopt a multi-pronged approach that aligns scientific ambition with pragmatic operational execution. First, prioritize investments in manufacturing automation and closed-system process development to reduce variability, lower labor dependency, and compress turnaround times. This operational foundation enables more consistent product quality and supports flexible responses to demand fluctuations.

Second, diversify supplier networks for critical inputs and implement strategic inventory policies to mitigate exposure to trade volatility and tariff-driven cost shifts. Simultaneously, evaluate nearshoring or regionalization of key production steps to reduce logistical complexity and improve responsiveness to regional markets. Third, pursue evidence-generation strategies that blend randomized data with real-world outcomes and registry-driven longitudinal follow-up to meet both regulatory and payer requirements for durable benefit.

Fourth, cultivate partnerships across academic, clinical, and manufacturing ecosystems to leverage external capabilities while retaining strategic control over core platform technologies. Fifth, engage early and iteratively with regulatory authorities and payers to define trial endpoints, health-economic models, and reimbursement mechanisms that align clinical value with sustainable pricing. Finally, strengthen commercial capabilities by developing outcome-based contracting frameworks and by building clinical support programs that facilitate adoption in diverse care settings. Together, these recommendations provide a roadmap to manage complexity while accelerating patient access and commercial viability.

A transparent, triangulated methodology combining expert interviews, clinical and regulatory documentation, and manufacturing process analysis to ensure robust and actionable insights

The research underpinning this executive summary synthesizes primary and secondary sources using a triangulated approach to ensure analytical rigor and relevance. Primary inputs included structured interviews with clinical investigators, manufacturing executives, and regulatory consultants, complemented by advisory sessions with payers and hospital administrators to capture operational and reimbursement perspectives. These qualitative inputs were systematically mapped against public regulatory filings, peer-reviewed literature, and industry disclosures to validate trends and identify divergences between claimed capabilities and observed operational performance.

Data analysis integrated process-level insights from manufacturing workshops with trial design and endpoint evaluations drawn from clinical registries and published studies. Where possible, methodological triangulation was applied by cross-referencing interview findings with documentary evidence and expert panel feedback. Quality control procedures included independent review of thematic findings, validation of technical assertions by subject-matter experts, and iterative refinement based on stakeholder responses. This layered approach ensured that conclusions reflect both the current state of technology and pragmatic operational constraints encountered in real-world deployment.

Synthesis of scientific promise and operational imperatives demonstrating that sustainable commercialization of T-cell therapies requires integrated technical, regulatory, and commercial execution

T-cell therapies occupy a transformative space in modern medicine, offering potentially durable solutions across oncology, infectious disease, and autoimmune indications. The field is simultaneously enabling clinical breakthroughs and confronting supply chain, manufacturing, and reimbursement realities that will determine the pace of patient access. Strategic decisions about cell source, therapeutic modality, manufacturing model, and regional expansion will be decisive for organizations aiming to translate scientific promise into lasting clinical and commercial impact.

Stakeholders who align technical innovation with operational scalability, regulatory foresight, and payer-centric evidence generation will derive competitive advantage. Conversely, those who underestimate the integration challenges across clinical, manufacturing, and commercial domains risk delayed launches and constrained uptake. In sum, the pathway to sustainable growth in T-cell therapy requires both continued scientific ingenuity and disciplined execution across the entire value chain.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancements in dual-target CAR T-cell therapies improving tumor specificity and safety profiles
  • 5.2. Integration of gene editing technologies like CRISPR to enhance T-cell persistence and efficacy
  • 5.3. Strategic partnerships between biotech startups and pharma giants to accelerate T-cell therapy commercialization
  • 5.4. Emergence of point-of-care manufacturing platforms to reduce CAR T-cell production times and costs
  • 5.5. Expansion of T-cell therapies into autoimmune and infectious disease indications beyond oncology pipelines
  • 5.6. Development of next-generation switchable CAR T-cells enabling controlled activation to mitigate cytokine release syndrome
  • 5.7. Increasing use of artificial intelligence and machine learning in optimizing T-cell manufacturing and patient selection
  • 5.8. Regulatory landscape evolution enabling accelerated approval pathways for T-cell therapies with real-world evidence support
  • 5.9. Adoption of universal donor T-cell platforms using genome editing to prevent graft-versus-host disease risks

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. T-Cell Therapy Market, by End User

  • 8.1. Hospital
  • 8.2. Research Institute
  • 8.3. Specialty Clinic

9. T-Cell Therapy Market, by Cell Source

  • 9.1. Allogeneic
  • 9.2. Autologous

10. T-Cell Therapy Market, by Indication

  • 10.1. Autoimmune Diseases
    • 10.1.1. Multiple Sclerosis
    • 10.1.2. Psoriasis
    • 10.1.3. Rheumatoid Arthritis
  • 10.2. Infectious Diseases
    • 10.2.1. Hepatitis B
    • 10.2.2. Hepatitis C
    • 10.2.3. HIV
  • 10.3. Oncology
    • 10.3.1. Leukemia
    • 10.3.2. Lymphoma
    • 10.3.3. Multiple Myeloma
    • 10.3.4. Solid Tumors
      • 10.3.4.1. Breast Cancer
      • 10.3.4.2. Lung Cancer
      • 10.3.4.3. Melanoma

11. T-Cell Therapy Market, by Therapy Type

  • 11.1. CAR T Cell Therapy
  • 11.2. TCR T Cell Therapy
  • 11.3. TIL Therapy

12. T-Cell Therapy Market, by Manufacturing Model

  • 12.1. Contract Manufacturing
  • 12.2. In-House Manufacturing

13. T-Cell Therapy Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. T-Cell Therapy Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. T-Cell Therapy Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Novartis AG
    • 16.3.2. Kite Pharma, Inc.
    • 16.3.3. Bristol-Myers Squibb Company
    • 16.3.4. Janssen Biotech, Inc.
    • 16.3.5. Gilead Sciences, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL T-CELL THERAPY MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL T-CELL THERAPY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL T-CELL THERAPY MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL T-CELL THERAPY MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL T-CELL THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS T-CELL THERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL T-CELL THERAPY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. T-CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. T-CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. T-CELL THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL T-CELL THERAPY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL T-CELL THERAPY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL T-CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL T-CELL THERAPY MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL T-CELL THERAPY MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL T-CELL THERAPY MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL T-CELL THERAPY MARKET SIZE, BY HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL T-CELL THERAPY MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL T-CELL THERAPY MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL T-CELL THERAPY MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL T-CELL THERAPY MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL T-CELL THERAPY MARKET SIZE, BY RESEARCH INSTITUTE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL T-CELL THERAPY MARKET SIZE, BY RESEARCH INSTITUTE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL T-CELL THERAPY MARKET SIZE, BY RESEARCH INSTITUTE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL T-CELL THERAPY MARKET SIZE, BY RESEARCH INSTITUTE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL T-CELL THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL T-CELL THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL T-CELL THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL T-CELL THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL T-CELL THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL T-CELL THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL T-CELL THERAPY MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL T-CELL THERAPY MARKET SIZE, BY ALLOGENEIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL T-CELL THERAPY MARKET SIZE, BY ALLOGENEIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL T-CELL THERAPY MARKET SIZE, BY ALLOGENEIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL T-CELL THERAPY MARKET SIZE, BY ALLOGENEIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL T-CELL THERAPY MARKET SIZE, BY ALLOGENEIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL T-CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL T-CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL T-CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL T-CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL T-CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL T-CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL T-CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL T-CELL THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL T-CELL THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL T-CELL THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL T-CELL THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL T-CELL THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL T-CELL THERAPY MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL T-CELL THERAPY MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL T-CELL THERAPY MARKET SIZE, BY PSORIASIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL T-CELL THERAPY MARKET SIZE, BY PSORIASIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL T-CELL THERAPY MARKET SIZE, BY PSORIASIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL T-CELL THERAPY MARKET SIZE, BY PSORIASIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL T-CELL THERAPY MARKET SIZE, BY PSORIASIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL T-CELL THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL T-CELL THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL T-CELL THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL T-CELL THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL T-CELL THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL T-CELL THERAPY MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL T-CELL THERAPY MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL T-CELL THERAPY MARKET SIZE, BY HEPATITIS B, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL T-CELL THERAPY MARKET SIZE, BY HEPATITIS B, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL T-CELL THERAPY MARKET SIZE, BY HEPATITIS B, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL T-CELL THERAPY MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL T-CELL THERAPY MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL T-CELL THERAPY MARKET SIZE, BY HEPATITIS C, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL T-CELL THERAPY MARKET SIZE, BY HEPATITIS C, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL T-CELL THERAPY MARKET SIZE, BY HEPATITIS C, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL T-CELL THERAPY MARKET SIZE, BY HEPATITIS C, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL T-CELL THERAPY MARKET SIZE, BY HEPATITIS C, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL T-CELL THERAPY MARKET SIZE, BY HEPATITIS C, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL T-CELL THERAPY MARKET SIZE, BY HIV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL T-CELL THERAPY MARKET SIZE, BY HIV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL T-CELL THERAPY MARKET SIZE, BY HIV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL T-CELL THERAPY MARKET SIZE, BY HIV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL T-CELL THERAPY MARKET SIZE, BY HIV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL T-CELL THERAPY MARKET SIZE, BY HIV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL T-CELL THERAPY MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL T-CELL THERAPY MARKET SIZE, BY LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL T-CELL THERAPY MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL T-CELL THERAPY MARKET SIZE, BY LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL T-CELL THERAPY MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL T-CELL THERAPY MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL T-CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL T-CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL T-CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL T-CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL T-CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL T-CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL T-CELL THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL T-CELL THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL T-CELL THERAPY MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL T-CELL THERAPY MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL T-CELL THERAPY MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL T-CELL THERAPY MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL T-CELL THERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL T-CELL THERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL T-CELL THERAPY MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL T-CELL THERAPY MARKET SIZE, BY LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL T-CELL THERAPY MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL T-CELL THERAPY MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL T-CELL THERAPY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL T-CELL THERAPY MARKET SIZE, BY MELANOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL T-CELL THERAPY MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL T-CELL THERAPY MARKET SIZE, BY MELANOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL T-CELL THERAPY MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL T-CELL THERAPY MARKET SIZE, BY MELANOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL T-CELL THERAPY MARKET SIZE, BY CAR T CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL T-CELL THERAPY MARKET SIZE, BY CAR T CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL T-CELL THERAPY MARKET SIZE, BY CAR T CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL T-CELL THERAPY MARKET SIZE, BY CAR T CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL T-CELL THERAPY MARKET SIZE, BY CAR T CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL T-CELL THERAPY MARKET SIZE, BY CAR T CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL T-CELL THERAPY MARKET SIZE, BY TCR T CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL T-CELL THERAPY MARKET SIZE, BY TCR T CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL T-CELL THERAPY MARKET SIZE, BY TCR T CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL T-CELL THERAPY MARKET SIZE, BY TCR T CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL T-CELL THERAPY MARKET SIZE, BY TCR T CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL T-CELL THERAPY MARKET SIZE, BY TCR T CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL T-CELL THERAPY MARKET SIZE, BY TIL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL T-CELL THERAPY MARKET SIZE, BY TIL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL T-CELL THERAPY MARKET SIZE, BY TIL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL T-CELL THERAPY MARKET SIZE, BY TIL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL T-CELL THERAPY MARKET SIZE, BY TIL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL T-CELL THERAPY MARKET SIZE, BY TIL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL T-CELL THERAPY MARKET SIZE, BY CONTRACT MANUFACTURING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL T-CELL THERAPY MARKET SIZE, BY CONTRACT MANUFACTURING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL T-CELL THERAPY MARKET SIZE, BY CONTRACT MANUFACTURING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL T-CELL THERAPY MARKET SIZE, BY CONTRACT MANUFACTURING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL T-CELL THERAPY MARKET SIZE, BY CONTRACT MANUFACTURING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL T-CELL THERAPY MARKET SIZE, BY CONTRACT MANUFACTURING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL T-CELL THERAPY MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL T-CELL THERAPY MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL T-CELL THERAPY MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL T-CELL THERAPY MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL T-CELL THERAPY MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL T-CELL THERAPY MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL T-CELL THERAPY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL T-CELL THERAPY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS T-CELL THERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS T-CELL THERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS T-CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS T-CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE T-CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE T-CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2025-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 284. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 285. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 286. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 288. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 290. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 291. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 292. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 294. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 296. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 297. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
  • TABLE 300. MIDDLE EAST T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2025-2032 (USD MILLION)
  • TABLE 301. AFRICA T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. AFRICA T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. AFRICA T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 304. AFRICA T-CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 305. AFRICA T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 306. AFRICA T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 307. AFRICA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 308. AFRICA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 309. AFRICA T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 310. AFRICA T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 311. AFRICA T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 312. AFRICA T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 313. AFRICA T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 314. AFRICA T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 315. AFRICA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 316. AFRICA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 317. AFRICA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 318. AFRICA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 319. AFRICA T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
  • TABLE 320. AFRICA T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2025-2032 (USD MILLION)
  • TABLE 321. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 322. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 323. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 324. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 325. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
  • TABLE 326. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
  • TABLE 327. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 328. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 329. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2024 (USD MILLION)
  • TABLE 330. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2025-2032 (USD MILLION)
  • TABLE 331. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 332. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 333. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 334. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 335. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 336. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 337. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 338. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 339. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2024 (USD MILLION)
  • TABLE 340. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2025-2032 (USD MILLION)
  • TABLE 341. GLOBAL T-CELL THERAPY MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 342. GLOBAL T-CELL THERAPY MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 343. ASEAN T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 344. ASEAN T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 345. ASEAN T-CELL THERAPY MARKET SIZE, BY END USER, 2018-